Q-omics provides the consensus-scored GDI1 profile across patient tissues and cancer cell-line models. GDI1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GDI1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GDI1 protein abundance shows 30,750 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, HNSC, and GBM as cancer lineages where GDI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GDI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GDI1 survival associations across molecular data types. GDI1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GDI1 RNA expression–survival associations across cancer types. High GDI1 expression shows unfavorable associations in COAD, ACC, HNSC, KICH, LUSC and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for GDI1 RNA expression.
This table summarizes GDI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GDI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GDI1 shows higher tumor expression in HNSC, COAD, LIHC, KIRC, BRCA and CHOL. The HNSC box plot shows higher GDI1 RNA expression in tumor versus normal tissue (log2 FC = +1.389, t-test p < 0.001).
This table shows molecular features associated with GDI1 in patient tissues and cancer cell lines. In patient samples, GDI1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GDI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
